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kA Randomized Trial of Decision-Making in Asymptomatic Carotid
Stenosis
Silver B, Zaman IF, Ashraf K, et al. Neurology 2012;78:315-21.
Conclusion: Presentation format (information framing) has a strong
influence on patient decision making with regard to management of asymp-
tomatic carotid stenosis.
Summary: Randomized trials of asymptomatic carotid stenosis have
shown a modest reduction in stroke risk when surgery is added to best
medical therapy. One can express, when discussing with patients, this
difference in multiple ways. The difference can be expressed as overall
absolute risk reduction (11% vs 5% over 5 years), relative risk reduction (50%
over 5 years), annualized absolute risk reduction (2% vs 1% per year over 5
years), absolute disease free survival (89% vs 95% over 5 years), or qualitative
description of benefit, such as significantly less strokes with surgery vs
medical therapy alone. There are also variables that may determine how
patients respond to proposed alternative treatments, including patient age,
sex, or race, as well as presenter age, sex, or race and how the information is
presented (so-called information framing, Nikolajevic-Sarunac J et al, J Gen
Intern Med 1999;14:591-8). This study sought to evaluate whether differ-
ent presentation formats, presenter factors, and patient factors affected
decision making regarding management of asymptomatic carotid stenosis.
Subjects were recruited through a neurology clinic. All subjects were aged
18 years, without known carotid stenosis. Once recruited, subjects were
randomized to a 30-second video with one of five presentation formats
(absolute risk, absolute event-free survival, annualized absolute risk, relative
risk, and qualitative description). Presentations were delivered by one of four
presenter physicians (black women, white women, black men, and white
men). After the presentation, subjects completed a 1-page form regarding
background demographics and their decision regarding treatment choice.
The video was watched and the survey completed by 409 subjects; overall,
48.4% chose surgery. The format of presentation strongly predicted choice
of surgery (qualitative [64%], relative risk [63%], absolute risk [43%],
absolute event-free survival [37%], and annualized absolute risk [35%]; P 
.001). There was a trend for younger age (mean age 52 vs 55 years; P 
.054), male sex (53% vs 45%; P  .08), and advanced education (42% for
high school education or less vs 52% for more than high school education;
P .052) to predict a choice for surgery. Sex and race of presenter and race
of subject had no influence of the choice of treatment.
Comment: The basic message is that it matters how you talk to
patients. There are, however, multiple limitations to this study. The authors
point out that the participants were only given information for 30 seconds
and were not given the opportunity to ask questions to clarify information.
It is therefore unclear whether the participants actually understood the
message transmitted. Also, the subjects were not actual patients, and the
entire cohort came from a specialty clinic of an urban hospital, making
generalization to patients in multiple settings problematic. Finally, the
participants did not actually have carotid stenosis. Despite the limitations,
the observations do provide a framework for understanding the potential
influences and variables in medical decision making, especially regarding
how complex information is presented to the patient. It is somewhat
gratifying to note that race and sex were not important variables influencing
patient decision in this study.
Comparable Effectiveness of Endovenous Laser Ablation and High
Ligation With Stripping of the Great Saphenous Vein: Two-Year
Results of a Randomized Clinical Trial (RELACS Study)
Rass K, Frings N, Glowacki P, et al. Arch Dermatol 2012;148:49-58.
Conclusion:High ligation and stripping (HLS) and endovascular laser
treatment (EVLT) are comparably safe and effective procedures to treat
great saphenous vein (GSV) incompetence.
Summary: GSV incompetence can be treated with HLS, EVLT, and
radiofrequency ablation (RFA). Although there are large case series of all
modalities of treatment for GSV incompetence, a limited number of ran-
domized trials have compared these therapies. This is the largest randomized
trial to date comparing EVLT with GSV stripping. The trial was conducted
in two centers and included 400 patients with GSV incompetence. Patients
were assigned (1:1) to EVLT or HLS from September 2004 throughMarch
2007. There were 185 limbs treated with EVLT per protocol and 161 limbs
treated with HLS. The primary study objective was to determine clinically
recurrent varicose veins after surgery. Other end points included determina-
tion of duplex-detected saphenofemoral reflux recurrence, clinical venous
severity scoring using theHomburg varicose vein severity score, venous refill
times, quality of life determined with the chronic venous insufficiency
r
g
276uestionnaire, and adverse effects and visual analog scale–based evaluations
f patient satisfaction. The percentage recurrence of varicose veins after
urgery was 16.2% in the EVLT group vs 23.1% in the HLS group, which
as similar. Although saphenofemoral reflux, as determined by duplex
canning, was more frequent after EVLT (17.8% vs 1.3%, P  .001) at 2
ears, both treatments resulted in equal improvement of the Homburg
aricose veins severity score and disease-related quality of life scores.
here were more adverse effects, such as phlebitic reaction, tightness,
nd dyspigmentation, with EVLT than with HLS. EVLT, however,
rovided minor advantages in patient evaluation of cosmetic outcome at
he 2-year follow-up.
Comment: This is the largest randomized trial comparing an en-
ovenous approach for the obliteration of the GSV with HLS. The results
re generally compatible with other studies, suggesting little difference
etween EVLT andHLS with regard to late and early outcomes. A review of
he literature as a whole, with regard to endovenous ablation, reveals about
0 randomized trials since 2005 comparing HLS with various forms of
ndovenous ablation. The trials are very heterogeneous, and only two
irectly compared EVLT with RFA. Nevertheless, taken as a whole, these
rials suggest relatively equal efficacy of all techniques for treatment of GSV
nsufficiency, with perhaps minor advantages for RFA with regard to post-
perative pain and early return to work and normal activities.
ondaparinux for Isolated Superficial Vein Thrombosis of the Legs: A
ost-Effectiveness Analysis
london M, Righini M, Bounameaux H, et al. Chest 2012;141:321-9.
Conclusion: Fondaparinux for 45 days is not cost-effective when
reating patients with isolated superficial venous thrombosis (SVT) of the
egs.
Summary: SVT is a frequent condition, and at the time diagnosis, up to
5% of patients may have associated deep venous thrombosis or pulmonary
mbolism (Decousus H et al, Ann Inter Med 2010;152:218-24). However,
atients recruited for the Decousus study were from vascular medicine
pecialists and may thus represent a population of more severe cases. Indeed,
he clinical impression is that although isolated SVT can on rare occasion be
ssociated with significant VTE events, in most cases, the disease has a very
enign course, at least in the short-term. Treatment of isolated SVT is
herefore controversial. The recently published Comparison of Arixtra in
ower Limb SVT With Placebo (CALISTO) study randomized 3000 pa-
ients with isolated lower extremity SVT to prophylactic fondaparinux (2.5
g daily for 45 days) vs placebo (Decousus H et al, N Engl J Med
010;363:1222-32). With respect to the composite outcomes of death,
eep venous thrombosis, and extension or recurrence of SVT, fondaparinux
as superior to placebo. There was, however, a high number needed to treat
o avoid one complication such as pulmonary embolism (n  300). Fonda-
arinux is expensive, and therefore, the authors of this study sought to
valuate its cost-effectiveness by creating decision-tree modeling with data
erived primarily from the CALISTO study and published literature. The
ecision-tree model compared fondaparinux (2.5mg daily for 45 days) vs no
reatment of SVT. The model included all clinical events associated with
VT, its treatment, complications, and all respective quality-adjustment
actors. Measured outcomes included VTE clinical events (major hemor-
hage, death) quality-adjusted life-years, (QALYs), cost, and incremental
ost-effectiveness ratios (ICERs). A lifetime time horizon analysis was used
rom a health care system perspective. One-way probabilistic sensitivity
nalysis was used to evaluate parameter uncertainty. In 10,000 patients, they
stimated that fondaparinux would prevent 123 VTE events and two deaths.
n a per-patient basis, incremental QALY compared with no treatment was
.04/day at an incremental cost of $1,734. This results in an ICER of
500,000 per QALY. ICER remained $100,000 per QALY with a one-
ay sensitivity analysis. Based on probabilistic sensitivity analysis, the prob-
bility that fondaparinux was cost-effective was 1% at a willingness-to-pay
100,000 per QALY.
Comment: The data indicate that fondaparinux as a blanket treatment
or SVT of the lower extremities is not anywhere near cost-effective based on
he commonly accepted threshold of$50,000 per QALY to guide recom-
endations in most clinical situations. The authors did not address whether
mproved cost-effectiveness could be achieved by targeting specific sub-
roups with SVT with a likely higher incidence of VTE. Such groups may
nclude men, those with severe chronic venous insufficiency, SVT without
aricose veins, and patients with a history of cancer, previous VTE, or a
nown thrombophilia. Future studies of SVT potentially could yield more
obust recommendations for treatment if higher-risk subgroups were tar-
eted in those studies.
